Earnings and Growth Analysis : Brooklyn ImmunoTherapeutics (NASDAQ:BTX)

Earnings results for Brooklyn ImmunoTherapeutics (NASDAQ:BTX)

Brooklyn ImmunoTherapeutics, Inc. is estimated to report earnings on 08/13/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-1.32.

Analyst Opinion on Brooklyn ImmunoTherapeutics (NASDAQ:BTX)

Dividend Strength: Brooklyn ImmunoTherapeutics (NASDAQ:BTX)

Brooklyn ImmunoTherapeutics does not currently pay a dividend. Brooklyn ImmunoTherapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Brooklyn ImmunoTherapeutics (NASDAQ:BTX)

In the past three months, Brooklyn ImmunoTherapeutics insiders have not sold or bought any company stock. 14.00% of the stock of Brooklyn ImmunoTherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Only 1.59% of the stock of Brooklyn ImmunoTherapeutics is held by institutions.

Earnings and Valuation of Brooklyn ImmunoTherapeutics (NASDAQ:BTX

The P/E ratio of Brooklyn ImmunoTherapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Brooklyn ImmunoTherapeutics is -3.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Brooklyn ImmunoTherapeutics has a P/B Ratio of 20.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here